https://www.biopharmawatch.com/news/PACS/pacs-post-acute-nursing-homes-2027 BiopharmaWatch en 2026-09-30T22:08:00.000Z Seventeen PACS Post-Acute Locations Named Top Nursing Homes for 2027 by Newsweek Magazine https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-announces-inducement-grant-nasdaq-listing-rule-5635-c BiopharmaWatch en 2026-09-30T21:46:00.000Z Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/BMY/fda-approves-expanded-indication-camzyos BiopharmaWatch en 2026-09-30T21:32:00.000Z U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb’s CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) in Adults and Pediatric Patients* https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-fpwr-symposium-2026 BiopharmaWatch en 2026-09-30T21:30:00.000Z Bright Minds Biosciences to Participate in the 2026 FPWR Research Symposium and PWS Family Conference https://www.biopharmawatch.com/news/CLGN/collplant-reports-2026-q2-financial-results BiopharmaWatch en 2026-09-30T21:20:00.000Z COLLPLANT REPORTS 2026 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE https://www.biopharmawatch.com/news/IMMX/immix-biopharma-closes-125-million-offering BiopharmaWatch en 2026-09-30T21:15:00.000Z Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock https://www.biopharmawatch.com/news/HCA/hca-healthcare-3q-2026-earnings-call BiopharmaWatch en 2026-09-30T21:03:00.000Z HCA Healthcare, Inc. 3rd Quarter 2026 Earnings Conference Call https://www.biopharmawatch.com/news/OCS/oculis-resignation-lionel-carnot-board BiopharmaWatch en 2026-09-30T20:46:00.000Z Oculis Announces Resignation of Lionel Carnot from Board of Directors https://www.biopharmawatch.com/news/LAB/standard-biotools-update-sale-mass-cytometry-business BiopharmaWatch en 2026-09-30T20:42:00.000Z Standard BioTools Provides Update on Sale of Mass Cytometry Business https://www.biopharmawatch.com/news/TEVA/tapi-names-serge-rogasik-ceo-growth-competitiveness BiopharmaWatch en 2026-09-30T20:32:00.000Z TAPI (Technology & API Services) Names Serge Rogasik CEO to lead next chapter of growth and competitiveness https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-nasdaq-listing-rule-5635-c-20260930 BiopharmaWatch en 2026-09-30T20:30:00.000Z Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/CVS/cvs-health-declares-quarterly-dividend-20260930 BiopharmaWatch en 2026-09-30T20:26:00.000Z CVS Health declares quarterly dividend https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-appoints-david-raben-cmo BiopharmaWatch en 2026-09-30T20:10:00.000Z Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer https://www.biopharmawatch.com/news/INGN/inogen-divestiture-us-oxygen-rental-business BiopharmaWatch en 2026-09-30T20:05:00.000Z Inogen Announces Divestiture of Its U.S. Oxygen Rental Business to Rotech https://www.biopharmawatch.com/news/CRVS/corvus-phase-1b-soquelitinib-hidradenitis-suppurativa BiopharmaWatch en 2026-09-30T20:05:00.000Z Corvus Pharmaceuticals Announces Initiation of Phase 1b Clinical Trial of Soquelitinib for Patients with Hidradenitis Suppurativa https://www.biopharmawatch.com/news/SCNX/scienture-holdings-reverse-stock-split BiopharmaWatch en 2026-09-30T20:05:00.000Z Scienture Holdings, Inc. Announces Reverse Stock Split https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-operational-highlights-h1-2026-results BiopharmaWatch en 2026-09-30T20:05:00.000Z RedHill Biopharma Announces Operational Highlights and First Half 2026 Financial Results https://www.biopharmawatch.com/news/HALO/halozyme-appoints-jim-daly-board-directors BiopharmaWatch en 2026-09-30T20:05:00.000Z Halozyme Announces Appointment of Jim Daly to its Board of Directors https://www.biopharmawatch.com/news/LGVN/longeveron-participate-longevity-investment-conferences BiopharmaWatch en 2026-09-30T20:05:00.000Z Longeveron to Participate in Three Longevity/Aging Investment Conferences https://www.biopharmawatch.com/news/ABVX/abivax-obefazimod-ueg-week-2026 BiopharmaWatch en 2026-09-30T20:05:00.000Z Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026 https://www.biopharmawatch.com/news/LTRN/lantern-pharma-inc-announces-closing-8-million-registered-direct-offering BiopharmaWatch en 2026-09-30T20:01:00.000Z Lantern Pharma Inc. Announces Closing of up to $8 Million Registered Direct Offering https://www.biopharmawatch.com/news/GLUE/monte-rosa-mrt-8102-gforce-1-phase-1-results BiopharmaWatch en 2026-09-30T20:01:00.000Z Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk https://www.biopharmawatch.com/news/HIT/health-in-tech-launches-hitrx-modernize-health-insurance BiopharmaWatch en 2026-09-30T20:00:00.000Z Health In Tech Launches HitRix to Modernize the Nearly $1 Trillion U.S. Self-Funded Health Insurance Market and Announces Updated 2026 Full-Year Revenue Guidance https://www.biopharmawatch.com/news/HCTI/healthcare-triangle-ai-humanoid-nursing-robots BiopharmaWatch en 2026-09-30T18:00:00.000Z Healthcare Triangle, Inc Signs MOU to Bring AI-Enabled Humanoid Nursing Robots to Hospitals in North America https://www.biopharmawatch.com/news/HSDT/solana-company-announces-15-million-offering BiopharmaWatch en 2026-09-30T17:57:00.000Z Solana Company (NASDAQ: HSDT) Announces Pricing of $15 Million Registered Direct Offering with a Global Institutional Investor https://www.biopharmawatch.com/news/LQDA/liquidia-update-hatch-waxman-litigation-patent-327 BiopharmaWatch en 2026-09-30T17:20:00.000Z Liquidia Provides Update on Hatch-Waxman Litigation Tied to ‘327 Patent https://www.biopharmawatch.com/news/RVP/retractable-technologies-declares-dividends-preferred-stock BiopharmaWatch en 2026-09-30T17:17:00.000Z Retractable Technologies, Inc. Declares Dividends to Series II and III Class B Preferred Stock Shareholders https://www.biopharmawatch.com/news/CELU/celularity-fontaine-vitale-opening-2027 BiopharmaWatch en 2026-09-30T15:57:00.000Z Celularity Highlights Anticipated Quarter One 2027 Opening of Fontaine Vitale as Strategic Partner https://www.biopharmawatch.com/news/NKTR/biomarker-data-rezpegaldesleukin-atopic-dermatitis BiopharmaWatch en 2026-09-30T14:30:00.000Z New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in Patients with Atopic Dermatitis https://www.biopharmawatch.com/news/QTTB/q32-bio-signal-aa-trial-results-2026 BiopharmaWatch en 2026-09-30T13:15:00.000Z Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026 https://www.biopharmawatch.com/news/SLGL/sol-gel-kol-investor-day-sgt-610-october-2026 BiopharmaWatch en 2026-09-30T13:14:00.000Z Sol-Gel Technologies to Host KOL Investor Day for SGT-610 on October 14, 2026 https://www.biopharmawatch.com/news/AGL/agilon-health-jackson-clinic-partnership-aco BiopharmaWatch en 2026-09-30T13:00:00.000Z agilon health and The Jackson Clinic Advance Their Partnership Through Senior Health Connect ACO https://www.biopharmawatch.com/news/BAX/baxter-connected-hospital-report-2026 BiopharmaWatch en 2026-09-30T13:00:00.000Z Baxter Releases Inaugural Connected Hospital Report https://www.biopharmawatch.com/news/DGX/ecg-screening-program-florida-high-school-athletes BiopharmaWatch en 2026-09-30T13:00:00.000Z Who We Play For and Myelai Launch Heart Screening Program at Quest Diagnostics in Tampa as Florida Becomes First State to Require ECGs for High School Athletes https://www.biopharmawatch.com/news/IDXX/idexx-acquires-covetai-chicago-pacific-founders-exit BiopharmaWatch en 2026-09-30T13:00:00.000Z Chicago Pacific Founders Pet Fund Announces Exit of CoVetAI Following Acquisition by IDEXX Laboratories https://www.biopharmawatch.com/news/ABT/abbott-third-quarter-earnings-call-2026 BiopharmaWatch en 2026-09-30T13:00:00.000Z Abbott hosts conference call for third-quarter earnings https://www.biopharmawatch.com/news/MDT/medtronic-regulatory-milestones-cardiac-mapping-software BiopharmaWatch en 2026-09-30T13:00:00.000Z Medtronic announces regulatory milestones for newest cardiac mapping and ablation software https://www.biopharmawatch.com/news/HQY/healthequity-appoints-noemie-heuland-board-directors BiopharmaWatch en 2026-09-30T13:00:00.000Z HealthEquity Appoints Moody’s CFO Noémie Heuland to Board of Directors https://www.biopharmawatch.com/news/HYPD/hyperion-defi-launches-institutional-credit-facility BiopharmaWatch en 2026-09-30T13:00:00.000Z Hyperion DeFi, Anchorage Digital, and HyperLend Together Announce the First Institutional Credit Facility on Hyperliquid https://www.biopharmawatch.com/news/ONMD/onemednet-signs-seven-figure-agreement-ai-data-solution BiopharmaWatch en 2026-09-30T12:55:00.000Z OneMedNet Signs Seven Figure Multiyear Agreement to Power a Partner Sold Derivative Data Solution https://www.biopharmawatch.com/news/SILO/silo-pharma-qwikagents-ai-platform-expansion BiopharmaWatch en 2026-09-30T12:50:00.000Z Silo Pharma’s QwikAgents Expands AI Agent Platform with NVIDIA Model Support and New Runtime Flexibility https://www.biopharmawatch.com/news/AIM/aim-immunotech-ampligen-pancreatic-cancer-therapy BiopharmaWatch en 2026-09-30T12:44:00.000Z AIM ImmunoTech Discusses Ampligen®’s Potential to Complement Emerging Pancreatic Cancer Therapies in New CEO Corner Video https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-mass-general-brigham-clinical-trial BiopharmaWatch en 2026-09-30T12:32:00.000Z Niagen Bioscience Announces Start-Up Agreement With Mass General Brigham (MGB) Investigators For First-Of-Its-Kind Healthy Aging Clinical Trial https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-erna-101-safety-results-ind-studies BiopharmaWatch en 2026-09-30T12:32:00.000Z Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND https://www.biopharmawatch.com/news/LNTH/lantheus-cms-grants-pylarity-truvu-status BiopharmaWatch en 2026-09-30T12:30:00.000Z Lantheus Announces CMS Grants Transitional Pass-Through Status for PYLARIFY® TruVu (piflufolastat F 18) https://www.biopharmawatch.com/news/DMAC/diamedica-kol-webinar-dm199-fgr-results BiopharmaWatch en 2026-09-30T12:30:00.000Z DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 for Fetal Growth Restriction Featuring Early Phase 2 FGR Results https://www.biopharmawatch.com/news/SRPT/sarepta-elevidys-data-world-muscle-society-2026 BiopharmaWatch en 2026-09-30T12:30:00.000Z Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with Duchenne https://www.biopharmawatch.com/news/NBIX/neurocrine-research-prader-willi-syndrome-vykat-xr BiopharmaWatch en 2026-09-30T12:30:00.000Z Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference https://www.biopharmawatch.com/news/LH/labcorp-third-quarter-2026-financial-results BiopharmaWatch en 2026-09-30T12:30:00.000Z Labcorp to Announce Third Quarter 2026 Financial Results on October 28, 2026 https://www.biopharmawatch.com/news/DCOY/decoy-therapeutics-small-cap-showcase-presentation BiopharmaWatch en 2026-09-30T12:30:00.000Z Decoy Therapeutics to Present at The Small Cap Showcase https://www.biopharmawatch.com/news/CADL/candel-therapeutics-announces-integrated-clinical-biomarker-data-showed-durable-local BiopharmaWatch en 2026-09-30T12:30:00.000Z Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer https://www.biopharmawatch.com/news/MRK/merck-tulisokibart-phase-2b-hidradenitis-suppurativa BiopharmaWatch en 2026-09-30T12:15:00.000Z Merck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 2b Study in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-tabelecleucel-bla-resubmission BiopharmaWatch en 2026-09-30T12:05:00.000Z Atara Biotherapeutics Reports that the Tabelecleucel Biologics License Application Has Been Resubmitted to the U.S. Food and Drug Administration https://www.biopharmawatch.com/news/CADL/candel-therapeutics-aglatimagene-prostate-cancer-astro-2026 BiopharmaWatch en 2026-09-30T12:05:00.000Z Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026 https://www.biopharmawatch.com/news/ARDX/ardelyx-honors-pm360-trailblazer-awards-2026 BiopharmaWatch en 2026-09-30T12:01:00.000Z Ardelyx Earns Multiple Honors at the 2026 PM360 Trailblazer Awards https://www.biopharmawatch.com/news/NCNA/nucana-grant-patent-nuc-7738-europe BiopharmaWatch en 2026-09-30T12:00:57.000Z NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in Europe https://www.biopharmawatch.com/news/BIAF/bioaffinity-avmedical-partnership-cypath-lung-cancer-test BiopharmaWatch en 2026-09-30T12:00:00.000Z bioAffinity Technologies Promotes Veteran Awareness and Access to Its Noninvasive CyPath® Lung Cancer Test Through Distribution Partnership with Veteran-Owned AvMEDICAL https://www.biopharmawatch.com/news/KARD/kardigan-appoints-kristin-reinke-board-directors BiopharmaWatch en 2026-09-30T12:00:00.000Z Kardigan Announces Appointment of Kristin Reinke to its Board of Directors https://www.biopharmawatch.com/news/CELC/celcuity-revtorpyk-commercial-availability BiopharmaWatch en 2026-09-30T12:00:00.000Z Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States https://www.biopharmawatch.com/news/AEON/aeon-biopharma-fda-feedback-abp-450-biosimilar-development BiopharmaWatch en 2026-09-30T12:00:00.000Z AEON Biopharma FDA Type 2b Meeting Feedback Clarifies Biosimilar Development Plan for ABP-450 https://www.biopharmawatch.com/news/TOVX/theriva-biologics-vcn-01-virage-phase-2b-results BiopharmaWatch en 2026-09-30T12:00:00.000Z Theriva™ Biologics Announces Publication of the Results from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer Published in Nature Medicine https://www.biopharmawatch.com/news/BSEM/biostem-technologies-3-million-private-placement BiopharmaWatch en 2026-09-30T12:00:00.000Z BioStem Technologies Announces $3 Million Private Placement Priced At-The-Market Under Nasdaq Rules https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-ycanthe-data-dermatology-conferences BiopharmaWatch en 2026-09-30T12:00:00.000Z Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology Conferences https://www.biopharmawatch.com/news/IMMP/immutep-receives-rd-tax-incentive BiopharmaWatch en 2026-09-30T12:00:00.000Z Immutep Receives ~A$0.86 Million R&D Tax Incentive https://www.biopharmawatch.com/news/EPRX/eupraxia-phase-1b-2a-resolve-trial-data-eprx BiopharmaWatch en 2026-09-30T12:00:00.000Z Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-announces-first-patient-successfully-dosed-phase-2-3 BiopharmaWatch en 2026-09-30T12:00:00.000Z Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer https://www.biopharmawatch.com/news/PMN/upcoming-conferences-events-october-2026 BiopharmaWatch en 2026-09-30T12:00:00.000Z Upcoming Conferences and Events in October https://www.biopharmawatch.com/news/INKT/mink-therapeutics-arpa-h-room-temperature-cell-therapy BiopharmaWatch en 2026-09-30T11:57:00.000Z MiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell Therapy https://www.biopharmawatch.com/news/IMNM/immunome-ind-clearance-im-1340-antibody-drug-conjugate BiopharmaWatch en 2026-09-30T11:45:00.000Z Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors https://www.biopharmawatch.com/news/ABUS/arbutus-preliminary-results-tender-offer BiopharmaWatch en 2026-09-30T11:30:00.000Z Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer https://www.biopharmawatch.com/news/CYTK/cytokinetics-launches-aspen-hcm-study-myorzo BiopharmaWatch en 2026-09-30T11:30:00.000Z Cytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO® (aficamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy https://www.biopharmawatch.com/news/CNSY/cerenome-cnside-third-quarter-update BiopharmaWatch en 2026-09-30T11:30:00.000Z Cerenome Expects $1.55 Million in CNSide® Third Quarter Gross Billings https://www.biopharmawatch.com/news/WVE/gsk-selects-waves-sirna-program-for-development BiopharmaWatch en 2026-09-30T11:30:00.000Z Wave Life Sciences Announces GSK’s Selection of siRNA program to Transition to GSK for Further Development https://www.biopharmawatch.com/news/EVGN/evogene-nasdaq-grants-180-day-compliance-period BiopharmaWatch en 2026-09-30T11:15:00.000Z Evogene Reports Nasdaq Grants Additional 180-Day Period to Regain Minimum Bid Price Compliance https://www.biopharmawatch.com/news/OCGN/ocugen-participate-scientific-conferences BiopharmaWatch en 2026-09-30T11:02:00.000Z Ocugen to Participate in Upcoming Scientific Conferences https://www.biopharmawatch.com/news/MSLE/satellos-completes-enrollment-basecamp-phase-2-trial BiopharmaWatch en 2026-09-30T11:00:00.000Z Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular Dystrophy https://www.biopharmawatch.com/news/CTSO/cytosorbents-new-data-presentations-conferences BiopharmaWatch en 2026-09-30T11:00:00.000Z CytoSorbents Announces New Data Presentations at Upcoming International Conferences in Cardiac Surgery and Critical Care https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-orphan-drug-designation-intranasal-foralumab BiopharmaWatch en 2026-09-30T11:00:00.000Z Tiziana Life Sciences Files for Orphan Drug Designation with the FDA for Intranasal Foralumab for the Treatment of Multiple System Atrophy (MSA) https://www.biopharmawatch.com/news/NRXP/nrx-defense-systems-darpa-contract-evaluate-robotic-tms BiopharmaWatch en 2026-09-30T11:00:00.000Z NRx Defense Systems, an NRx Company (Nasdaq:NRXP) Awarded $11 Million Dollar DARPA Prime Contract to Evaluate Robotic Magnetic Stimulation in conjunction with NRX-101 for Treatment of Resistant Depression https://www.biopharmawatch.com/news/CBLL/ceribell-fda-clearance-eeg-software BiopharmaWatch en 2026-09-30T11:00:00.000Z Ceribell Receives FDA 510(k) Clearance for Quantitative EEG Trending and Amplitude-Integrated EEG Analysis https://www.biopharmawatch.com/news/HROW/harrow-ophthalmic-portfolio-aaopt-aao-2026 BiopharmaWatch en 2026-09-30T11:00:00.000Z Harrow Ophthalmic Portfolio Highlighted in 15 Scientific Presentations at AAOpt and AAO https://www.biopharmawatch.com/news/JBIO/jade-biosciences-preclinical-data-jade301-dermatomyositis BiopharmaWatch en 2026-09-30T11:00:00.000Z Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026 https://www.biopharmawatch.com/news/KLRA/kailera-therapeutics-kainetic-phase-3-enrollment-completed BiopharmaWatch en 2026-09-30T11:00:00.000Z Kailera Therapeutics Announces Completion of Enrollment in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide Injection https://www.biopharmawatch.com/news/CNTB/connect-biopharma-announces-positive-preliminary-topline-data-global-phase-2 BiopharmaWatch en 2026-09-30T11:00:00.000Z Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation https://www.biopharmawatch.com/news/ANL/adlai-nortye-appoints-christopher-liu-head-investor-relations BiopharmaWatch en 2026-09-30T11:00:00.000Z Adlai Nortye Appoints Christopher Liu, PharmD, as Head of Investor Relations and Public Relations https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-fluocinolone-acetonide-data-aao-2026 BiopharmaWatch en 2026-09-30T10:55:00.000Z ANI Pharmaceuticals Announces New Fluocinolone Acetonide Intravitreal Implant Data to be Presented at the American Academy of Ophthalmology 2026 Annual Meeting https://www.biopharmawatch.com/news/HSIC/henry-schein-cares-25-years-health-happen BiopharmaWatch en 2026-09-30T10:30:00.000Z Henry Schein Cares Marks 25 Years of Helping Health Happen® https://www.biopharmawatch.com/news/CMPS/compass-pathways-appoints-kelley-boucher-cpo BiopharmaWatch en 2026-09-30T10:30:00.000Z Compass Pathways Appoints Kelley Boucher as Chief People Officer https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-offering-115-million BiopharmaWatch en 2026-09-30T10:19:00.000Z Sagimet Biosciences Announces Pricing of $115.0 Million Underwritten Offering of Series A Common Stock and Pre-Funded Warrants https://www.biopharmawatch.com/news/SGMT/sagimet-positive-results-denifanstat-acne-trial BiopharmaWatch en 2026-09-30T10:00:00.000Z Sagimet Announces Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne Presented at EADV 2026 https://www.biopharmawatch.com/news/ABBV/abbvie-phase-1-data-abbv-295-easd-2026 BiopharmaWatch en 2026-09-30T09:45:00.000Z AbbVie Presents Detailed Phase 1 Data for ABBV-295, a Long-Acting Amylin Analog, Demonstrating Favorable Tolerability and Pharmacokinetic Profile at EASD 2026 https://www.biopharmawatch.com/news/ABBV/abbvie-phase-2-apex-study-zumilokibart-results BiopharmaWatch en 2026-09-30T05:30:00.000Z AbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at EADV 2026 https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-public-offering-pricing BiopharmaWatch en 2026-09-30T05:11:00.000Z Pyxis Oncology Announces Pricing of Up to $282.6 Million Public Offering https://www.biopharmawatch.com/news/TAK/zasocitinib-efficacy-deucravacitinib-phase-3-results BiopharmaWatch en 2026-09-30T05:00:00.000Z Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill https://www.biopharmawatch.com/news/ABBV/abbvie-dermatology-research-eadv-congress-2026 BiopharmaWatch en 2026-09-30T05:00:00.000Z AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV Congress https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-positive-phase-iii-results-hetlioz BiopharmaWatch en 2026-09-29T22:45:00.000Z Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ®(tasimelteon) in Delayed Sleep-Wake Phase Disorder https://www.biopharmawatch.com/news/DBVT/dbv-technologies-submission-biologics-license-application BiopharmaWatch en 2026-09-29T22:29:00.000Z DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years https://www.biopharmawatch.com/news/BETR/betterlife-pharma-agm-rescheduled-special-meeting BiopharmaWatch en 2026-09-29T21:59:00.000Z BetterLife Pharma Announces Rescheduling and Reclassification of Annual General Meeting to Annual General and Special Meeting https://www.biopharmawatch.com/news/MRVL/marvel-biosciences-private-placement-3-million BiopharmaWatch en 2026-09-29T21:52:00.000Z Marvel Biosciences Announces Closing of Private Placement For Up To $3.0 Million https://www.biopharmawatch.com/news/GANX/gain-therapeutics-poster-presentation-parkinsons-congress BiopharmaWatch en 2026-09-29T21:50:00.000Z Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson’s Disease and Movement Disorders https://www.biopharmawatch.com/news/ROVA/altrova-health-debt-settlement BiopharmaWatch en 2026-09-29T21:02:00.000Z Altrova Health Closes Debt Settlement https://www.biopharmawatch.com/news/HCA/hca-healthcare-2026-awards-distinction BiopharmaWatch en 2026-09-29T20:30:00.000Z HCA Healthcare Presents 2026 Awards of Distinction https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-proposed-public-offering BiopharmaWatch en 2026-09-29T20:24:00.000Z Pyxis Oncology Announces Proposed Public Offering https://www.biopharmawatch.com/news/ARDT/university-kansas-health-system-ardent-health-transition-ownership BiopharmaWatch en 2026-09-29T20:15:00.000Z The University of Kansas Health System and Ardent Health Announce Plans to Transition Ownership of St. Francis Campus https://www.biopharmawatch.com/news/IQV/iqvia-third-quarter-2026-results-announcement BiopharmaWatch en 2026-09-29T20:15:00.000Z IQVIA to Announce Third-Quarter 2026 Results on October 27, 2026 https://www.biopharmawatch.com/news/IMUX/immunic-inducement-grants-nasdaq-rule-5635 BiopharmaWatch en 2026-09-29T20:05:00.000Z Immunic Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-announces-additional-one-year-clinical-data-phase-1 BiopharmaWatch en 2026-09-29T20:05:00.000Z Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) https://www.biopharmawatch.com/news/EQ/equillium-poster-presentations-ahr-conference BiopharmaWatch en 2026-09-29T20:05:00.000Z Equillium Announces Poster Presentations at the 7th International AHR Conference https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-john-harlow-appointment BiopharmaWatch en 2026-09-29T20:05:00.000Z Larimar Therapeutics Strengthens Executive Leadership with Appointment of John Harlow as President and Chief Operating Officer https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-reports-inducement-awards-nasdaq-listing-rule-5635-c-20260929 BiopharmaWatch en 2026-09-29T20:05:00.000Z Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/MRVI/trilink-secures-china-patent-cleancap-technology BiopharmaWatch en 2026-09-29T20:01:00.000Z TriLink BioTechnologies® Secures Additional China Patent for CleanCap® Technology, Adding Broad Composition-of-Matter Protection to Reinforce Its Global IP https://www.biopharmawatch.com/news/AVTX/avalo-therapeutics-inducement-grants-employees-nasdaq BiopharmaWatch en 2026-09-29T20:01:00.000Z Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/ARVN/arvinas-inducement-grant-nasdaq-listing-rule-5635c4 BiopharmaWatch en 2026-09-29T20:01:00.000Z Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/CUPR/cuprina-holdings-closing-underwriters-over-allotment-option BiopharmaWatch en 2026-09-29T20:00:00.000Z Cuprina Holdings (Cayman) Limited Announces Closing of Underwriter’s Over-Allotment Option in Connection with Public Offering https://www.biopharmawatch.com/news/WELL/well-health-wellstar-amalgamation-completion BiopharmaWatch en 2026-09-29T19:30:00.000Z WELL Health Subsidiary WELLSTAR Announces Completion of Amalgamation and Expected Trading Date of "WSTR" on TSXV https://www.biopharmawatch.com/news/VTRS/viatris-worlds-best-employers-sixth-year BiopharmaWatch en 2026-09-29T18:00:00.000Z Viatris Recognized by Forbes as One of the World's Best Employers for the Sixth Consecutive Year https://www.biopharmawatch.com/news/HCA/solis-mammography-hca-healthcare-charleston-partnership BiopharmaWatch en 2026-09-29T15:36:00.000Z SOLIS MAMMOGRAPHY AND HCA HEALTHCARE CHARLESTON PARTNER TO EXPAND BREAST HEALTH SERVICES IN SOUTH CAROLINA https://www.biopharmawatch.com/news/GMAB/genmab-s-published-articles-association-20260929 BiopharmaWatch en 2026-09-29T13:32:30.000Z Genmab A/S has published its Articles of Association https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-pelareorep-liver-cancer-immunotherapy BiopharmaWatch en 2026-09-29T13:30:00.000Z Oncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy https://www.biopharmawatch.com/news/VALN/new-approach-to-travel-health-valn BiopharmaWatch en 2026-09-29T13:15:47.000Z A changing world, a new approach to travel health https://www.biopharmawatch.com/news/ARQT/simone-biles-arcutis-skin-to-believe-in-campaign BiopharmaWatch en 2026-09-29T13:15:31.000Z Simone Biles Partners with Arcutis to Launch the Skin to Believe In Campaign, Raising Awareness of Seborrheic Dermatitis and Eczema, and Inspiring People to Explore Treatment Options https://www.biopharmawatch.com/news/ERNA/ernexa-selected-emerging-track-cell-gene-meeting BiopharmaWatch en 2026-09-29T13:15:00.000Z Ernexa Therapeutics Selected for Emerging Track at 2026 Cell & Gene Meeting on the Mesa, Highlighting ERNA-101 and Focused Oncology Strategy https://www.biopharmawatch.com/news/TXG/10x-genomics-sentira-computational-platform-launch BiopharmaWatch en 2026-09-29T13:01:00.000Z 10x Genomics Announces Sentira, a New Computational Platform to Turn Complex Biological Data Into Experimental Conclusions https://www.biopharmawatch.com/news/ALNY/amvuttra-play-by-play-initiative-attr-cm BiopharmaWatch en 2026-09-29T13:00:00.000Z AMVUTTRA® (vutrisiran) ‘Play by Play’ Initiative Highlights Former Athletes’ Stories to Shine a Light on the Often-Missed Signs of ATTR-CM https://www.biopharmawatch.com/news/BDX/bdx-70-years-manufacturing-sandy-utah BiopharmaWatch en 2026-09-29T13:00:00.000Z BD Celebrates 70 Years of Manufacturing, Innovation and Community Partnership in Sandy https://www.biopharmawatch.com/news/TXG/10x-genomics-begins-global-shipments-of-atera BiopharmaWatch en 2026-09-29T13:00:00.000Z 10x Genomics Begins Global Shipments of Atera, Putting Unprecedented Spatial Biology Capabilities in Researchers' Hands https://www.biopharmawatch.com/news/ABBV/abbvie-partners-valkai-advanced-ai-clinical-development BiopharmaWatch en 2026-09-29T13:00:00.000Z AbbVie Partners with Valkai to Apply Advanced AI Across Targeted Areas of Clinical Development https://www.biopharmawatch.com/news/NXL/nexalin-technology-global-commercialization-strategy BiopharmaWatch en 2026-09-29T13:00:00.000Z Nexalin Technology Taps Neuromodulation Commercial Executive Robert DiTota to Advise on its Global Commercialization Strategy https://www.biopharmawatch.com/news/LIMN/liminatus-pharma-regains-compliance-nasdaq-minimum-bid-price BiopharmaWatch en 2026-09-29T13:00:00.000Z Liminatus Pharma Regains Compliance with Nasdaq Minimum Bid Price Rule https://www.biopharmawatch.com/news/NTHI/neonc-s-powerful-brain-cancer-pipeline-advances BiopharmaWatch en 2026-09-29T12:52:00.000Z NeOnc’s Powerful Brain Cancer Pipeline Advances https://www.biopharmawatch.com/news/MBRX/moleculin-biotech-phase-2-3-miracle-trial-enrollment-complete BiopharmaWatch en 2026-09-29T12:45:00.000Z Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-cost-reduction-revenue-growth BiopharmaWatch en 2026-09-29T12:45:00.000Z Vivos Therapeutics Reports Progress in Material Cost Reductions and Revenue Growth Initiatives https://www.biopharmawatch.com/news/ICU/seastar-medical-cmo-presents-ppets-2026 BiopharmaWatch en 2026-09-29T12:36:00.000Z SeaStar Medical Announces Chief Medical Officer, Kevin Chung, M.D., to Present at the Pediatric Paracorporeal and Extracorporeal Therapy Symposium (PPETS) 2026 https://www.biopharmawatch.com/news/AIDX/2020-biolabs-investor-webinar-fda-vote-onetest BiopharmaWatch en 2026-09-29T12:31:00.000Z 20/20 BioLabs to Host Investor Webinar on October 7, 2026 to Discuss FDA Advisory Committee Vote and New OneTest™ Franchise Model https://www.biopharmawatch.com/news/APLI/appili-therapeutics-transfer-nex BiopharmaWatch en 2026-09-29T12:30:00.000Z Appili Therapeutics Announces Transfer to NEX https://www.biopharmawatch.com/news/QTI/qt-imaging-nasdaq-closing-bell-breast-cancer-awareness BiopharmaWatch en 2026-09-29T12:30:00.000Z QT Imaging to Ring the Nasdaq Closing Bell on October 2 in Recognition of Breast Cancer Awareness Month https://www.biopharmawatch.com/news/FBLG/fibrobiologics-european-patent-fibroblast-therapy BiopharmaWatch en 2026-09-29T12:30:00.000Z FibroBiologics Announces Grant of European Patent for Methods of Enhancing Fibroblast Therapeutic Activity https://www.biopharmawatch.com/news/CELU/celularity-naveen-jain-board-appointment BiopharmaWatch en 2026-09-29T12:30:00.000Z Celularity Announces Naveen Jain to Join Board of Directors https://www.biopharmawatch.com/news/LITS/lite-strategy-fiscal-year-2026-results BiopharmaWatch en 2026-09-29T12:30:00.000Z Lite Strategy Reports Fiscal Year 2026 Financial Results https://www.biopharmawatch.com/news/PPCB/propanc-biopharma-corporate-update-financial-results-2026 BiopharmaWatch en 2026-09-29T12:30:00.000Z Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results https://www.biopharmawatch.com/news/TARS/tarsus-presents-11-abstracts-aaopt-2026 BiopharmaWatch en 2026-09-29T12:30:00.000Z Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual Meeting https://www.biopharmawatch.com/news/MLSS/milestone-scientific-scalable-growth-platform-compuflo BiopharmaWatch en 2026-09-29T12:30:00.000Z Milestone Scientific Highlights Building a Scalable Growth Platform for CompuFlo® Medical Business https://www.biopharmawatch.com/news/IART/integra-lifesciences-aera-pediatric-registry-100th-patient BiopharmaWatch en 2026-09-29T12:30:00.000Z Integra LifeSciences Announces 100th Patient Enrolled in AERA® Pediatric Registry https://www.biopharmawatch.com/news/VOR/telitacicept-minimal-symptom-expression-gmg BiopharmaWatch en 2026-09-29T12:05:27.000Z Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-exercise-warrants BiopharmaWatch en 2026-09-29T12:03:00.000Z Silexion Therapeutics Announces Exercise of Warrants https://www.biopharmawatch.com/news/PFE/isomab-appoints-bill-sessa-chair-scientific-advisory-board BiopharmaWatch en 2026-09-29T12:03:00.000Z Professor Bill Sessa, Former Chief Scientific Officer of Internal Medicine at Pfizer, Appointed Chair of Isomab's Scientific Advisory Board https://www.biopharmawatch.com/news/ACXP/acurx-pathfinder-trial-ibezapolstat-cdi BiopharmaWatch en 2026-09-29T12:01:00.000Z Acurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile Infection https://www.biopharmawatch.com/news/ADIA/adia-labs-expansion-regenerative-product-line BiopharmaWatch en 2026-09-29T12:00:00.000Z Adia Med Inc. Announces Adia Labs Expansion of Regenerative Product Line https://www.biopharmawatch.com/news/ABBV/ginkgo-apheris-abbvie-argenx-lundbeck-takeda-consortium BiopharmaWatch en 2026-09-29T12:00:00.000Z Ginkgo Datapoints and Apheris Welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium https://www.biopharmawatch.com/news/A/agilent-gen5-ai-cell-identification-module-launch BiopharmaWatch en 2026-09-29T12:00:00.000Z Agilent Introduces Gen5 AI Cell Identification Module for BioTek Automated Cell Imagers https://www.biopharmawatch.com/news/LTRN/lantern-pharma-8-million-offering BiopharmaWatch en 2026-09-29T12:00:00.000Z Lantern Pharma Inc. Announces up to $8 Million Registered Direct Offering https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-cvr-shareholders-voucher BiopharmaWatch en 2026-09-29T12:00:00.000Z Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher https://www.biopharmawatch.com/news/NVS/cas-gibt-zusammenarbeit-mit-novartis-bekannt-um-die-ki-fahige BiopharmaWatch en 2026-09-29T12:00:00.000Z CAS gibt Zusammenarbeit mit Novartis bekannt, um die KI-fähige Reaktionsinformatik voranzutreiben https://www.biopharmawatch.com/news/NVS/cas-novartis-ai-research-collaboration BiopharmaWatch en 2026-09-29T12:00:00.000Z CAS anuncia una colaboración con Novartis para impulsar la informática de reacciones preparada para la IA https://www.biopharmawatch.com/news/NVS/cas-novartis-ai-reaction-informatics BiopharmaWatch en 2026-09-29T12:00:00.000Z CAS announces collaboration with Novartis to advance AI-ready reaction informatics https://www.biopharmawatch.com/news/IMNN/imunon-debt-to-equity-conversion BiopharmaWatch en 2026-09-29T12:00:00.000Z IMUNON Converts $1.2 Million of Debt-to-Equity https://www.biopharmawatch.com/news/POCI/precision-optics-lytham-partners-fall-2026-conference BiopharmaWatch en 2026-09-29T12:00:00.000Z Precision Optics to Participate in the Lytham Partners Fall 2026 Investor Conference https://www.biopharmawatch.com/news/BBNX/beta-bionics-third-quarter-2026-results-announcement BiopharmaWatch en 2026-09-29T12:00:00.000Z Beta Bionics to Announce Third Quarter 2026 Financial Results on October 27, 2026 https://www.biopharmawatch.com/news/TECX/tectonic-therapeutic-phase-1-results-tx2100-hht BiopharmaWatch en 2026-09-29T12:00:00.000Z Tectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT) https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-spinoza-trial-obicetrapib-alzheimers BiopharmaWatch en 2026-09-29T12:00:00.000Z NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease https://www.biopharmawatch.com/news/APYX/apyx-medical-renuvion-clinical-study-results BiopharmaWatch en 2026-09-29T12:00:00.000Z Apyx Medical Announces New Clinical Study Demonstrating Renuvion®’s Impact on Skin Quality https://www.biopharmawatch.com/news/PHAT/phathom-phase-3-study-voquezna-non-erosive-gerd BiopharmaWatch en 2026-09-29T12:00:00.000Z Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD https://www.biopharmawatch.com/news/NSRX/nasus-pharma-phase-1-study-ns003-ondansetron BiopharmaWatch en 2026-09-29T12:00:00.000Z Nasus Pharma Announces Enrollment and Dosing of First Patient in Phase 1 Study of NS003 Intranasal Formulation of Ondansetron https://www.biopharmawatch.com/news/DNTH/dianthus-claseprubart-2026-aanem-meeting BiopharmaWatch en 2026-09-29T12:00:00.000Z Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2026 AANEM Annual Meeting https://www.biopharmawatch.com/news/KROS/keros-therapeutics-takeda-milestone-payment BiopharmaWatch en 2026-09-29T12:00:00.000Z Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda https://www.biopharmawatch.com/news/ARGX/argenx-new-data-aanem-mgfa-sessions BiopharmaWatch en 2026-09-29T12:00:00.000Z argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline https://www.biopharmawatch.com/news/STRO/sutro-biopharma-appoints-lucas-donigian-business-development BiopharmaWatch en 2026-09-29T12:00:00.000Z Sutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business Development https://www.biopharmawatch.com/news/CRBP/corbus-tempo-1-study-crb-701-oropharyngeal-cancer BiopharmaWatch en 2026-09-29T12:00:00.000Z Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer https://www.biopharmawatch.com/news/IQST/edison-report-on-iqstel BiopharmaWatch en 2026-09-29T11:53:00.000Z Edison Issues Report on iQSTEL (IQST) https://www.biopharmawatch.com/news/RHEL/rhelion-life-sciences-pex010-phase-2-trial-ptsd BiopharmaWatch en 2026-09-29T11:53:00.000Z Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Ships PEX010 to the University of Calgary for Phase 2 Trial of Psilocybin-Assisted Therapy for PTSD in Survivors of Intimate Partner Violence https://www.biopharmawatch.com/news/GLAS/glass-house-brands-cfo-retirement-announcement BiopharmaWatch en 2026-09-29T11:35:00.000Z Glass House Brands Announces Planned Retirement of Chief Financial Officer https://www.biopharmawatch.com/news/ARWR/arrowhead-webinar-aro-mapt-alzheimers-study BiopharmaWatch en 2026-09-29T11:30:00.000Z Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies https://www.biopharmawatch.com/news/DCOY/decoy-therapeutics-preclinical-data-intranasal-dosing BiopharmaWatch en 2026-09-29T11:30:00.000Z Decoy Therapeutics Reports Preclinical Data Supporting Once-Weekly Intranasal Dosing for DCOY-CoV Program https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-phase-2-clover-wam-data BiopharmaWatch en 2026-09-29T11:30:00.000Z Cellectar Biosciences to Present Compelling Efficacy Data from Phase 2 CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Refractory/Resistant to BTK Inhibitor Therapy at International Workshop for Waldenström Macroglobulinemia https://www.biopharmawatch.com/news/MDCX/medicus-pharma-teverelix-fda-submission BiopharmaWatch en 2026-09-29T11:30:00.000Z Medicus Pharma Submits Optimized Teverelix® Registrational Protocol to FDA to Create Partner Ready Program in Advanced Prostate Cancer https://www.biopharmawatch.com/news/OPTH/optimi-health-appoints-melanie-pump-board-directors BiopharmaWatch en 2026-09-29T11:30:00.000Z Optimi Health Appoints Melanie Pump to Board of Directors https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-descartes-08-retreatment-data BiopharmaWatch en 2026-09-29T11:30:00.000Z Cartesian Therapeutics Announces Additional Retreatment Data for Descartes-08 Highlighting Deep and Durable Responses in Patients with Myasthenia Gravis https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-schedules-type-c-meeting-fda-align-endpoints-phase BiopharmaWatch en 2026-09-29T11:30:00.000Z Cognition Therapeutics Schedules a Type C Meeting with FDA to Align on Endpoints for Phase 3 Trial of Zervimesine (CT1812) in DLB https://www.biopharmawatch.com/news/QURE/uniqure-phase-i-ii-ifezuntirgene-inilparvovec-huntingtons-disease BiopharmaWatch en 2026-09-29T11:12:00.000Z uniQure Announces Additional Data from Ongoing Phase I/II Studies of ifezuntirgene inilparvovec (AMT-130) in Huntington’s Disease Showing Continued Slowing of Disease Progression https://www.biopharmawatch.com/news/IMCC/im-cannabis-sale-imc-holdings-european-operations BiopharmaWatch en 2026-09-29T11:07:00.000Z IM Cannabis Announces Closing of the Sale of IMC Holdings and Its European-Focused Operations, Strengthens Balance Sheet https://www.biopharmawatch.com/news/UNCY/unicycive-therapeutics-resubmission-ndas-oxylanthanum-carbonate BiopharmaWatch en 2026-09-29T11:05:00.000Z Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate https://www.biopharmawatch.com/news/IMMX/immix-biopharma-125-million-offering BiopharmaWatch en 2026-09-29T11:05:00.000Z Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock https://www.biopharmawatch.com/news/OCGN/ocugen-participate-october-investor-conferences BiopharmaWatch en 2026-09-29T11:02:00.000Z Ocugen to Participate in Upcoming October Investor and Industry Conferences https://www.biopharmawatch.com/news/BYSI/beyondspring-fda-fast-track-plinabulin-nsclc-trial BiopharmaWatch en 2026-09-29T11:01:00.000Z BeyondSpring Announces FDA Fast Track Designation for Plinabulin in Post-ICI Non-Squamous NSCLC and Strategic Transaction to Advance Global Phase 3 DUBLIN-4 Trial Toward Planned Interim Analysis https://www.biopharmawatch.com/news/IVVD/invivyd-liberty-phase-3-study-results-vyd2311 BiopharmaWatch en 2026-09-29T11:01:00.000Z Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311 https://www.biopharmawatch.com/news/BHST/bioharvest-sciences-share-repurchase-program BiopharmaWatch en 2026-09-29T11:00:00.000Z BioHarvest Sciences Announces Share Repurchase Program https://www.biopharmawatch.com/news/ALDX/aldeyra-fdr-request-reproxalap-dry-eye-disease BiopharmaWatch en 2026-09-29T11:00:00.000Z Aldeyra Therapeutics Announces Intent to Submit Formal Dispute Resolution Request for Reproxalap to Treat Dry Eye Disease https://www.biopharmawatch.com/news/ZLAB/zai-lab-global-data-zocilurtatug-es-sclc BiopharmaWatch en 2026-09-29T11:00:00.000Z Zai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-raises-revenue-guidance-2026 BiopharmaWatch en 2026-09-29T11:00:00.000Z Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-rich-daly-appointment BiopharmaWatch en 2026-09-29T11:00:00.000Z Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-pfizer-collaboration-milestone BiopharmaWatch en 2026-09-29T11:00:00.000Z Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer https://www.biopharmawatch.com/news/NRXS/neuraxis-appoints-craig-blanchard-cfo BiopharmaWatch en 2026-09-29T11:00:00.000Z NeurAxis Positions for Next Phase of Commercial Growth with Appointment of Craig Blanchard as Chief Commercial Officer https://www.biopharmawatch.com/news/ACON/aclarion-nyu-langone-health-clarity-trial-network BiopharmaWatch en 2026-09-29T11:00:00.000Z Aclarion Welcomes NYU Langone Health to CLARITY Trial Network, Now Enrolling at Eleven Sites https://www.biopharmawatch.com/news/IMMX/immix-biopharma-nexicart-2-interim-update BiopharmaWatch en 2026-09-29T11:00:00.000Z Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relapsed/Refractory AL Amyloidosis https://www.biopharmawatch.com/news/OKYO/okyo-pharma-ophthalmic-conferences-2026 BiopharmaWatch en 2026-09-29T11:00:00.000Z OKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific Conferences https://www.biopharmawatch.com/news/TFX/teleflex-reduces-clabsi-risk-arrowgard-technology BiopharmaWatch en 2026-09-29T10:30:00.000Z Teleflex Announces Latest Peer-Reviewed Study Demonstrates a Significant Reduction in CLABSI Risk with Arrowg+ard™ Technology https://www.biopharmawatch.com/news/CAI/caris-life-sciences-enhanced-caris-assure-launch BiopharmaWatch en 2026-09-29T10:30:00.000Z Caris Life Sciences Unveils the Next Evolution of Liquid Biopsy with Enhanced Caris Assure https://www.biopharmawatch.com/news/GENFF/genflow-biosciences-announces-warrant-exercise BiopharmaWatch en 2026-09-29T09:32:00.000Z Genflow Biosciences PLC Announces Exercise of Warrants and Issue of Equity https://www.biopharmawatch.com/news/COSM/cosmos-health-cosmo-farm-revenue-growth BiopharmaWatch en 2026-09-29T09:30:00.000Z Cosmos Health's CosmoFarm Reaches Record Annualized Revenue Above $60 Million, Up 4.3x Under Cosmos Health Ownership, as Robotics and AI Build Capacity to Support Over $100 Million in Annualized Revenue https://www.biopharmawatch.com/news/KURA/caspian-therapeutics-ko-7246-easd-diabetes BiopharmaWatch en 2026-09-29T09:15:00.000Z Caspian Therapeutics Unveils KO-7246 at EASD as a Potential Best-In-Class Menin Inhibitor for Diabetes https://www.biopharmawatch.com/news/NNVC/nanoviricides-nv387-phase-ii-trials-report BiopharmaWatch en 2026-09-29T08:45:00.000Z NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials https://www.biopharmawatch.com/news/TELO/telo-genomics-telemrd-clinical-research-results BiopharmaWatch en 2026-09-29T07:30:00.000Z Telo Genomics Reports Additional Clinical Research Results Comparing Blood-Based TELO-MRD with Bone-Marrow Next-Generation Flow and Next-Generation Sequencing https://www.biopharmawatch.com/news/DTC/defence-therapeutics-appoints-sherry-aulin-board BiopharmaWatch en 2026-09-29T07:15:00.000Z Defence Therapeutics Appoints Finance Executive Sherry Aulin to Its Board of Directors https://www.biopharmawatch.com/news/EVO/evotec-chief-scientific-officer-transition BiopharmaWatch en 2026-09-29T06:04:00.000Z Evotec Announces Chief Scientific Officer Transition https://www.biopharmawatch.com/news/PHAR/pharming-ceo-transition-announcement BiopharmaWatch en 2026-09-29T05:00:00.000Z Pharming announces CEO transition https://www.biopharmawatch.com/news/JAGX/crofelemer-study-results-acg-2026 BiopharmaWatch en 2026-09-29T04:30:00.000Z Preliminary Results of Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer Accepted for Presentation at Annual American College of Gastroenterology Meeting https://www.biopharmawatch.com/news/GENFF/genflow-biosciences-half-year-financial-report-2026 BiopharmaWatch en 2026-09-29T02:00:00.000Z Genflow Biosciences PLC Announces Half-year Financial Report https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-azure-1-study-brelovitug BiopharmaWatch en 2026-09-29T00:34:00.000Z Resumen: Mirum Pharmaceuticals anuncia que se ha cumplido el criterio de valoración principal en el estudio de fase III AZURE-1 sobre brelovitug para tratar la hepatitis crónica por el virus delta https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-phase-3-azure-1-study BiopharmaWatch en 2026-09-29T00:34:00.000Z Mirum Pharmaceuticals gibt bekannt, dass der primäre Endpunkt in der Phase-3-Studie AZURE-1 zu Brelovitug bei chronischer Hepatitis-Delta-Virus-Infektion erreicht wurde https://www.biopharmawatch.com/news/BLTE/belite-bio-upcoming-medical-conferences BiopharmaWatch en 2026-09-29T00:00:00.000Z Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences